MabSpace Starts US Trial of PD-L1 Drug; China Trial to Begin Soon

MabSpace Biosciences of Suzhou has dosed the first patient in a US Phase I trial of MSB2311, its second generation PD-L1 treatment for advanced solid tumors. It is the first MabSpace molecule to begin clinical trials. In China , MSB2311 is in the late stages of the CFDA review process, and MabSpace expects it will start a China Phase I trial soon. Using its proprietary platform MabSpace provides discovery services to other biopharmas and is also developing its own portfolio of six immuno-oncology antibodies, which are designed to work in combination with MSB2311. More details.... Share this with colleagues: // //